Biohaven Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Selling, General & Admin	104.33	89.24	62.77	130.86	37.41	16.05
Research & Development	833.03	784.97	373.28	437.07	181.49	98.46
Operating Expenses	937.36	874.21	436.05	567.93	218.9	114.51
Operating Income	-937.36	-874.21	-436.05	-567.93	-218.9	-114.51
Earnings From Equity Investments	-	-	-	-	5.26	-4.16
Other Non Operating Income (Expenses)	14.96	18.09	8.81	-5.12	1.21	-
EBT Excluding Unusual Items	-922.4	-856.12	-427.24	-573.05	-212.43	-118.67
Gain (Loss) on Sale of Investments	20.29	21.33	17.69	3.21	-	-
Other Unusual Items	136	-10.9	-	-	-	-
Pretax Income	-766.11	-845.69	-409.55	-569.84	-212.43	-118.67
Income Tax Expense	0.86	0.74	-1.38	0.44	1.37	-
Net Income	-766.97	-846.42	-408.17	-570.28	-213.8	-118.67
Net Income to Common	-766.97	-846.42	-408.17	-570.28	-213.8	-118.67
Shares Outstanding (Basic)	100	91	71	45	39	39
Shares Outstanding (Diluted)	100	91	71	45	39	39
Shares Change (YoY)	26.59%	28.14%	59.14%	13.63%	-	-
EPS (Basic)	-7.65	-9.28	-5.73	-12.75	-5.43	-3.01
EPS (Diluted)	-7.65	-9.28	-5.73	-12.75	-5.43	-3.01
Free Cash Flow	-646.43	-586.5	-334.77	-303.76	-146.78	-78.65
Free Cash Flow Per Share	-6.45	-6.43	-4.70	-6.79	-3.73	-2.00
EBITDA	-928.68	-866.36	-429.14	-566.55	-217.51	-114.43
D&A For EBITDA	8.68	7.86	6.91	1.39	1.39	0.07
EBIT	-937.36	-874.21	-436.05	-567.93	-218.9	-114.51

Updated Aug 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q